Brief: Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
07/03/2024 12:30
March 7 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE II
TRIAL FOR LSALT PEPTIDE TARGETING CARDIAC SURGERY
ASSOCIATED-ACUTE KIDNEY INJURY
Source text for Eikon: ID:nGNX87jDDM
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide